<DOC>
	<DOCNO>NCT01090414</DOCNO>
	<brief_summary>This long-term safety extension study idelalisib ( GS-1101 ; CAL-101 ) patient hematologic malignancy complete idelalisib study . It provide opportunity patient continue treatment long patient derive clinical benefit . Patients follow accord standard care appropriate type cancer . The dose idelalisib generally dose administered end prior study , may titrate improve clinical response toxicity . Patients withdraw study develop progressive disease , unacceptable toxicity relate idelalisib , longer derive clinical benefit opinion investigator .</brief_summary>
	<brief_title>An Extension Study Subjects Who Are Deriving Benefit With Idelalisib ( GS-1101 ; CAL-101 ) Following Completion Prior Idelalisib Study</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Patients hematologic malignancy complete prior idelalisib study clinical benefit eligible Women childbearing potential must negative pregnancy test eligible Male patient , female patient childbearing potential , must agree use method ( ) contraception specify protocol Patients unwilling unable comply protocol eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Idelalisib</keyword>
	<keyword>Chronic lymphocytic leukemia ( CLL )</keyword>
	<keyword>Non-Hodgkin lymphoma ( NHL )</keyword>
	<keyword>Phosphatidylinositol 3-kinase ( PI3K )</keyword>
</DOC>